BMJ Rapid Recommendations for Therapeutic Drug Monitoring of Biologics in Patients with Inflammatory Bowel Disease, Inflammatory Arthritis, or Psoriasis

Published by Per Olav Vandvik on Oct 27, 2024

Disclaimer

Sponsors

Contact

Abstract

Language

en

PICOS

PICO 20.1

Population
Patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis
Intervention
Proactive TDM (maintenance infliximab)
Comparator
Standard care
Outcomes

PICO 20.2

Population
Patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis
Intervention
Proactive TDM (maintenance adalimumab)
Comparator
Standard care
Outcomes

PICO 20.3

Population
Patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis
Intervention
Proactive TDM (maintenance other biologicals)
Comparator
Standard care
Outcomes

PICO 30.1

Population
Patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis
Intervention
Proactive TDM (induction infliximab)
Comparator
Standard care
Outcomes

PICO 30.2

Population
Patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis
Intervention
Proactive TDM (induction adalimumab, other biologicals)
Comparator
Standard of Care
Outcomes